CytoMed Therapeutics Forms Strategic Partnership with SUNACT for Cancer Treatment Trials

Key Information Extracted from the Financial Report (Form 6-K)

1. Filing Details:

• Type: Form 6-K
• Commission File Number: 001-41677
• Filing Date: January 6, 2025

2. Company Information:

• Name: CytoMed Therapeutics Limited
• Address: 1 Commonwealth Lane #08-22, Singapore 149544

3. Business Collaboration:

• Partner: Sunact Cancer Institute Private Limited (SUNACT)
• Agreement: Business Research Collaboration Agreement (BRCA) dated December 30, 2024.
• Purpose: To jointly establish and conduct clinical trials for unmodified gamma delta T Cells, aimed at treating solid tumors.
• Territory: The collaboration covers South Asia (including Bangladesh, Bhutan, India, the Maldives, Nepal, Pakistan, Sri Lanka, and Afghanistan) and Dubai.

4. Roles and Responsibilities:

• CytoMed Therapeutics: Responsible for manufacturing and supplying the product, providing scientific expertise, laboratory support, and clinical data management.
• SUNACT: Will lead clinical trial operations, including regulatory approvals, patient recruitment, and trial guidance.

5. Joint Venture:

• A new Joint Venture Company (JVC) will be established with an initial 50/50 shareholding structure between the two organizations.

6. Regulatory Timeline:

• Both parties must submit relevant applications for clinical trial approval within 12 months of signing the agreement.
• Collaborative efforts will continue into the commercialization phase after successful clinical trials.

7. Additional Filings:

• The company has also filed Form S-8 with the Securities and Exchange Commission on the same date (January 6, 2025).

8. Exhibit:

• A press release titled "CytoMed Therapeutics signs Business & Research Collaboration Agreement with India’s SunAct Cancer Institute Private Limited to advance use of allogeneic off-the-shelf Gamma Delta T Cells for treatment of solid cancers in a proposed Phase 2 clinical trial in India" is included as Exhibit 99.1.

Insights:

• This collaboration highlights CytoMed's strategic move to expand its clinical research capabilities and market presence in South Asia.
• The establishment of a Joint Venture indicates a commitment to shared risk and resource pooling, potentially enhancing the effectiveness of the clinical trials.
• The requirement for timely submission of regulatory applications emphasizes the urgency and planned progression of this initiative.

Overall, the report indicates a significant step for CytoMed Therapeutics in advancing its product offerings through strategic partnerships, aiming to leverage clinical and manufacturing expertise to enter new markets.